登入選單
返回Google圖書搜尋
Cardiac Muscle Function In Cancer-Related Fatigue
註釋CARDIAC MUSCLE FUNCTION IN CANCER-RELATED FATIGUEIntroduction Cancer-related fatigue (CRF) is a common, high-impact symptom but pathophysiology is unclear. One possible mechanism dysfunction of cardiac muscle. Cancer-related changes to cardiac muscle may precede any treatment-related cardiotoxicity. Cardiac biomarkers can be abnormal, even with normal cardiac imaging. Myocardial strain is a sensitive method of measuring left ventricular (LV) function.Objectives To investigate CRF and cardiac function in people with solid tumour malignancies. Methods Treatment nau00efve participants were recruited from medical oncology outpatient clinics. Fatigue was measured subjectively (brief fatigue inventory [BFI]) and objectively (grip strength, timed-up-and-go [TUG] and sit-to-stand [STS]). BFI u22653 was indicative of fatigue.A 2D transthoracic echocardiogram assessed cardiac function (systolic: ejection fraction [EF]; diastolic: isovolumic relaxation time [IVRT, LV relaxation] and mitral valve E/A ratio [E/A, LV filling velocities]. Left ventricular (LV) myocardial strain was analysed using EchoPAC software (GE Healthcareu2122). A cardiac biomarker, NT-pro brain natriuretic peptide (NT-BNP), was measured on a subset of participants who were scheduled for chemotherapy. Results u2022t45 participants (30F)u2022tAge: Median 57 (range 38-82)u2022tCancer type: Breast 28, Oesophageal 16, Prostate 1 u2022tLoco-regional disease: 26u2022tBFI: Median 1.7 (range 0-7.7)u2022tBFI u22653: 14/45 (31%)tFatiguedMedian (range)N=14tNon-FatiguedMedian (range)N=31Hand grip strength (kg force)t21 (7-33)t25 (13-48)TUG (s)t8 (6-12)t7 (5-10)STS (number in 30s)t13 (6-16)t14 (8-25)LVEF (%, normal u226555)t68 (63-80)t69 (54-84)Mitral valve E/A (ratio, normal >1)t0.96 (0.3-1.8)t1.2 (0.6-2.1)IVRT (ms, normal 80u00b112)t98 (88-133)t106 (70-124)tN=11tN=29Global longitudinal strain (%, normal 16-22)t18 (16-24)t19 (15-25)tN=7tN=22NT-BNP (ng/L, normal